APA (7th ed.) Citation

Ren, H., Zhang, W., Ouyang, Y., Guo, J., Xu, H., Ma, J., . . . Chen, N. (2025). A phase 4, open-label, multicenter study of the safety and efficacy of agalsidase beta in Chinese patients with Fabry disease. Orphanet Journal of Rare Diseases, 20(1), 1. https://doi.org/10.1186/s13023-025-03950-7

Chicago Style (17th ed.) Citation

Ren, Hong, et al. "A Phase 4, Open-label, Multicenter Study of the Safety and Efficacy of Agalsidase Beta in Chinese Patients with Fabry Disease." Orphanet Journal of Rare Diseases 20, no. 1 (2025): 1. https://doi.org/10.1186/s13023-025-03950-7.

MLA (9th ed.) Citation

Ren, Hong, et al. "A Phase 4, Open-label, Multicenter Study of the Safety and Efficacy of Agalsidase Beta in Chinese Patients with Fabry Disease." Orphanet Journal of Rare Diseases, vol. 20, no. 1, 2025, p. 1, https://doi.org/10.1186/s13023-025-03950-7.